APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Peptide-Radionuclide Conjugates (PRCs)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Peptide-Radionuclide Conjugates (PRCs) Market Analysis and Forecast 2026-2032

Report ID 174023660229 December 2025198 pages

Choose your research edition.

Industry ResearchPeptide-Radionuclide Conjugates (PRCs) Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide-Radionuclide Conjugates (PRCs) Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Peptide-Radionuclide Conjugates (PRCs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide-Radionuclide Conjugates (PRCs) Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide-Radionuclide Conjugates (PRCs) Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Peptide-Radionuclide Conjugates (PRCs) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Peptide-Radionuclide Conjugates (PRCs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Peptide-Radionuclide Conjugates (PRCs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Peptide-Radionuclide Conjugates (PRCs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Peptide-Radionuclide Conjugates (PRCs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Peptide-Radionuclide Conjugates (PRCs) include Grand Pharmaceutical, Novartis, Telix Pharmaceutical, RadioMedix, ITM Radiopharma and Curium Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Peptide-Radionuclide Conjugates (PRCs), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Peptide-Radionuclide Conjugates (PRCs), also provides the sales of main regions and countries. Of the upcoming market potential for Peptide-Radionuclide Conjugates (PRCs), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptide-Radionuclide Conjugates (PRCs) sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Peptide-Radionuclide Conjugates (PRCs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Peptide-Radionuclide Conjugates (PRCs) sales, projected growth trends, production technology, application and end-user industry.

Peptide-Radionuclide Conjugates (PRCs) Segment by Company

Grand Pharmaceutical

Novartis

Telix Pharmaceutical

RadioMedix

ITM Radiopharma

Curium Pharma

Peptide-Radionuclide Conjugates (PRCs) Segment by Type

Diagnostic PRCs

Therapeutic PRCs

Peptide-Radionuclide Conjugates (PRCs) Segment by Application

Prostate Cancer

Neuroendocrine Tumors

Other

Peptide-Radionuclide Conjugates (PRCs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide-Radionuclide Conjugates (PRCs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide-Radionuclide Conjugates (PRCs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide-Radionuclide Conjugates (PRCs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Peptide-Radionuclide Conjugates (PRCs) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Peptide-Radionuclide Conjugates (PRCs) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide-Radionuclide Conjugates (PRCs) sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Peptide-Radionuclide Conjugates (PRCs) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Diagnostic PRCs Major Manufacturers Table 3. Therapeutic PRCs Major Manufacturers Table 4. Global Peptide-Radionuclide Conjugates (PRCs) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Prostate Cancer Major Manufacturers Table 6. Neuroendocrine Tumors Major Manufacturers Table 7. Other Major Manufacturers Table 8. Peptide-Radionuclide Conjugates (PRCs) Industry Trends Table 9. Peptide-Radionuclide Conjugates (PRCs) Industry Drivers Table 10. Peptide-Radionuclide Conjugates (PRCs) Industry Opportunities and Challenges Table 11. Peptide-Radionuclide Conjugates (PRCs) Industry Restraints Table 12. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Region (2021-2026) Table 16. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Region (2027-2032) Table 17. Global Peptide-Radionuclide Conjugates (PRCs) Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region (2021-2026) & (K Units) Table 19. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region (2027-2032) & (K Units) Table 20. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Region (2021-2026) Table 21. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Region (2027-2032) Table 22. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Manufacturers (2021-2026) Table 26. Global Peptide-Radionuclide Conjugates (PRCs) Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Peptide-Radionuclide Conjugates (PRCs) Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Peptide-Radionuclide Conjugates (PRCs) Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Peptide-Radionuclide Conjugates (PRCs) Manufacturers, Product Type & Application Table 30. Global Peptide-Radionuclide Conjugates (PRCs) Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Peptide-Radionuclide Conjugates (PRCs) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Type (2021-2026) Table 37. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Type (2027-2032) Table 38. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026) & (K Units) Table 40. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2027-2032) & (K Units) Table 41. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021-2026) Table 42. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2027-2032) Table 43. Global Peptide-Radionuclide Conjugates (PRCs) Price by Type (2021-2026) & (US$/Unit) Table 44. Global Peptide-Radionuclide Conjugates (PRCs) Price by Type (2027-2032) & (US$/Unit) Table 45. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Application (2021-2026) Table 49. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Application (2027-2032) Table 50. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026) & (K Units) Table 52. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2027-2032) & (K Units) Table 53. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2021-2026) Table 54. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2027-2032) Table 55. Global Peptide-Radionuclide Conjugates (PRCs) Price by Application (2021-2026) & (US$/Unit) Table 56. Global Peptide-Radionuclide Conjugates (PRCs) Price by Application (2027-2032) & (US$/Unit) Table 57. Grand Pharmaceutical Company Information Table 58. Grand Pharmaceutical Business Overview Table 59. Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolio Table 61. Grand Pharmaceutical Recent Development Table 62. Novartis Company Information Table 63. Novartis Business Overview Table 64. Novartis Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Novartis Peptide-Radionuclide Conjugates (PRCs) Product Portfolio Table 66. Novartis Recent Development Table 67. Telix Pharmaceutical Company Information Table 68. Telix Pharmaceutical Business Overview Table 69. Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolio Table 71. Telix Pharmaceutical Recent Development Table 72. RadioMedix Company Information Table 73. RadioMedix Business Overview Table 74. RadioMedix Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. RadioMedix Peptide-Radionuclide Conjugates (PRCs) Product Portfolio Table 76. RadioMedix Recent Development Table 77. ITM Radiopharma Company Information Table 78. ITM Radiopharma Business Overview Table 79. ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolio Table 81. ITM Radiopharma Recent Development Table 82. Curium Pharma Company Information Table 83. Curium Pharma Business Overview Table 84. Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolio Table 86. Curium Pharma Recent Development Table 87. North America Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021-2026) & (US$ Million) Table 88. North America Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2027-2032) & (US$ Million) Table 89. North America Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026) & (K Units) Table 90. North America Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2027-2032) & (K Units) Table 91. North America Peptide-Radionuclide Conjugates (PRCs) Sales Price by Type (2021-2026) & (US$/Unit) Table 92. North America Peptide-Radionuclide Conjugates (PRCs) Sales Price by Type (2027-2032) & (US$/Unit) Table 93. North America Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021-2026) & (US$ Million) Table 94. North America Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2027-2032) & (US$ Million) Table 95. North America Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026) & (K Units) Table 96. North America Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2027-2032) & (K Units) Table 97. North America Peptide-Radionuclide Conjugates (PRCs) Sales Price by Application (2021-2026) & (US$/Unit) Table 98. North America Peptide-Radionuclide Conjugates (PRCs) Sales Price by Application (2027-2032) & (US$/Unit) Table 99. North America Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. North America Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 101. North America Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 102. North America Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 103. North America Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026) & (K Units) Table 104. North America Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2027-2032) & (K Units) Table 105. North America Peptide-Radionuclide Conjugates (PRCs) Sales Price by Country (2021-2026) & (US$/Unit) Table 106. North America Peptide-Radionuclide Conjugates (PRCs) Sales Price by Country (2027-2032) & (US$/Unit) Table 107. United States Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 108. Canada Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 109. Mexico Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 110. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021-2026) & (US$ Million) Table 111. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2027-2032) & (US$ Million) Table 112. Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026) & (K Units) Table 113. Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2027-2032) & (K Units) Table 114. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Price by Type (2021-2026) & (US$/Unit) Table 115. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Price by Type (2027-2032) & (US$/Unit) Table 116. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021-2026) & (US$ Million) Table 117. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2027-2032) & (US$ Million) Table 118. Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026) & (K Units) Table 119. Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2027-2032) & (K Units) Table 120. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Price by Application (2021-2026) & (US$/Unit) Table 121. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Price by Application (2027-2032) & (US$/Unit) Table 122. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 123. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 124. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 125. Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 126. Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026) & (K Units) Table 127. Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2027-2032) & (K Units) Table 128. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Price by Country (2021-2026) & (US$/Unit) Table 129. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Price by Country (2027-2032) & (US$/Unit) Table 130. Germany Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 131. France Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 132. U.K. Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 133. Italy Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 134. Russia Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 135. Spain Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 136. Netherlands Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 137. Switzerland Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 138. Sweden Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 139. Poland Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 140. China Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021-2026) & (US$ Million) Table 141. China Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2027-2032) & (US$ Million) Table 142. China Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026) & (K Units) Table 143. China Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2027-2032) & (K Units) Table 144. China Peptide-Radionuclide Conjugates (PRCs) Sales Price by Type (2021-2026) & (US$/Unit) Table 145. China Peptide-Radionuclide Conjugates (PRCs) Sales Price by Type (2027-2032) & (US$/Unit) Table 146. China Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021-2026) & (US$ Million) Table 147. China Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2027-2032) & (US$ Million) Table 148. China Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026) & (K Units) Table 149. China Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2027-2032) & (K Units) Table 150. China Peptide-Radionuclide Conjugates (PRCs) Sales Price by Application (2021-2026) & (US$/Unit) Table 151. China Peptide-Radionuclide Conjugates (PRCs) Sales Price by Application (2027-2032) & (US$/Unit) Table 152. Asia Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021-2026) & (US$ Million) Table 153. Asia Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2027-2032) & (US$ Million) Table 154. Asia Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026) & (K Units) Table 155. Asia Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2027-2032) & (K Units) Table 156. Asia Peptide-Radionuclide Conjugates (PRCs) Sales Price by Type (2021-2026) & (US$/Unit) Table 157. Asia Peptide-Radionuclide Conjugates (PRCs) Sales Price by Type (2027-2032) & (US$/Unit) Table 158. Asia Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021-2026) & (US$ Million) Table 159. Asia Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2027-2032) & (US$ Million) Table 160. Asia Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026) & (K Units) Table 161. Asia Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2027-2032) & (K Units) Table 162. Asia Peptide-Radionuclide Conjugates (PRCs) Sales Price by Application (2021-2026) & (US$/Unit) Table 163. Asia Peptide-Radionuclide Conjugates (PRCs) Sales Price by Application (2027-2032) & (US$/Unit) Table 164. Asia Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 165. Asia Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 166. Asia Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 167. Asia Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 168. Asia Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026) & (K Units) Table 169. Asia Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2027-2032) & (K Units) Table 170. Asia Peptide-Radionuclide Conjugates (PRCs) Sales Price by Country (2021-2026) & (US$/Unit) Table 171. Asia Peptide-Radionuclide Conjugates (PRCs) Sales Price by Country (2027-2032) & (US$/Unit) Table 172. Japan Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 173. South Korea Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 174. India Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 175. Australia Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 176. Taiwan Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 177. Southeast Asia Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 178. SAMEA Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021-2026) & (US$ Million) Table 179. SAMEA Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2027-2032) & (US$ Million) Table 180. SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026) & (K Units) Table 181. SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2027-2032) & (K Units) Table 182. SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales Price by Type (2021-2026) & (US$/Unit) Table 183. SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales Price by Type (2027-2032) & (US$/Unit) Table 184. SAMEA Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021-2026) & (US$ Million) Table 185. SAMEA Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2027-2032) & (US$ Million) Table 186. SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026) & (K Units) Table 187. SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2027-2032) & (K Units) Table 188. SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales Price by Application (2021-2026) & (US$/Unit) Table 189. SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales Price by Application (2027-2032) & (US$/Unit) Table 190. SAMEA Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 191. SAMEA Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 192. SAMEA Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 193. SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 194. SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026) & (K Units) Table 195. SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2027-2032) & (K Units) Table 196. SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales Price by Country (2021-2026) & (US$/Unit) Table 197. SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales Price by Country (2027-2032) & (US$/Unit) Table 198. Brazil Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 199. Argentina Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 200. Chile Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 201. Colombia Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 202. Peru Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 203. Saudi Arabia Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 204. Israel Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 205. UAE Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 206. Turkey Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 207. Iran Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 208. Egypt Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Table 209. Key Raw Materials Table 210. Raw Materials Key Suppliers Table 211. Peptide-Radionuclide Conjugates (PRCs) Distributors List Table 212. Peptide-Radionuclide Conjugates (PRCs) Customers List Table 213. Research Programs/Design for This Report Table 214. Authors List of This Report Table 215. Secondary Sources Table 216. Primary Sources List of Figures Figure 1. Peptide-Radionuclide Conjugates (PRCs) Image Figure 2. Global Peptide-Radionuclide Conjugates (PRCs) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide-Radionuclide Conjugates (PRCs) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Diagnostic PRCs Image Figure 5. Therapeutic PRCs Image Figure 6. Global Peptide-Radionuclide Conjugates (PRCs) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Peptide-Radionuclide Conjugates (PRCs) Market Size Share 2021 VS 2025 VS 2032 Figure 8. Prostate Cancer Image Figure 9. Neuroendocrine Tumors Image Figure 10. Other Image Figure 11. Global Peptide-Radionuclide Conjugates (PRCs) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Figure 13. Global Peptide-Radionuclide Conjugates (PRCs) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Region (2021-2032) Figure 16. Global Peptide-Radionuclide Conjugates (PRCs) Sales (2021-2032) & (K Units) Figure 17. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Peptide-Radionuclide Conjugates (PRCs) Sales YoY (2021-2032) & (K Units) Figure 20. Europe Peptide-Radionuclide Conjugates (PRCs) Sales YoY (2021-2032) & (K Units) Figure 21. China Peptide-Radionuclide Conjugates (PRCs) Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Peptide-Radionuclide Conjugates (PRCs) Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Sales YoY (2021-2032) & (K Units) Figure 24. Global Peptide-Radionuclide Conjugates (PRCs) Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Peptide-Radionuclide Conjugates (PRCs) Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Type (2021-2032) Figure 30. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021-2032) Figure 33. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Application (2021-2032) Figure 36. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2021-2032) Figure 39. North America Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Type (2021-2032) Figure 40. North America Peptide-Radionuclide Conjugates (PRCs) Sales Share by Type (2021-2032) Figure 41. North America Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Application (2021-2032) Figure 42. North America Peptide-Radionuclide Conjugates (PRCs) Sales Share by Application (2021-2032) Figure 43. North America Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Country (2021-2032) Figure 44. North America Peptide-Radionuclide Conjugates (PRCs) Sales Share by Country (2021-2032) Figure 45. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Type (2021-2032) Figure 46. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Share by Type (2021-2032) Figure 47. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Application (2021-2032) Figure 48. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Share by Application (2021-2032) Figure 49. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Country (2021-2032) Figure 50. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Share by Country (2021-2032) Figure 51. China Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Type (2021-2032) Figure 52. China Peptide-Radionuclide Conjugates (PRCs) Sales Share by Type (2021-2032) Figure 53. China Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Application (2021-2032) Figure 54. China Peptide-Radionuclide Conjugates (PRCs) Sales Share by Application (2021-2032) Figure 55. Asia Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Type (2021-2032) Figure 56. Asia Peptide-Radionuclide Conjugates (PRCs) Sales Share by Type (2021-2032) Figure 57. Asia Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Application (2021-2032) Figure 58. Asia Peptide-Radionuclide Conjugates (PRCs) Sales Share by Application (2021-2032) Figure 59. Asia Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Country (2021-2032) Figure 60. Asia Peptide-Radionuclide Conjugates (PRCs) Sales Share by Country (2021-2032) Figure 61. SAMEA Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Type (2021-2032) Figure 62. SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales Share by Type (2021-2032) Figure 63. SAMEA Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Application (2021-2032) Figure 64. SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales Share by Application (2021-2032) Figure 65. SAMEA Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Country (2021-2032) Figure 66. SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales Share by Country (2021-2032) Figure 67. Peptide-Radionuclide Conjugates (PRCs) Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Peptide-Radionuclide Conjugates (PRCs) Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Diagnostic PRCs
  • Therapeutic PRCs
Applications
  • Prostate Cancer
  • Neuroendocrine Tumors
  • Other
Companies covered
  • Grand Pharmaceutical
  • Novartis
  • Telix Pharmaceutical
  • RadioMedix
  • ITM Radiopharma
  • Curium Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Peptide-Radionuclide Conjugates (PRCs) Market by Type
  3. 1.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Diagnostic PRCs
  5. 1.2.3 Therapeutic PRCs
  6. 1.3 Peptide-Radionuclide Conjugates (PRCs) Market by Application
  7. 1.3.1 Global Peptide-Radionuclide Conjugates (PRCs) Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Prostate Cancer
  9. 1.3.3 Neuroendocrine Tumors
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Peptide-Radionuclide Conjugates (PRCs) Market Dynamics
  1. 2.1 Peptide-Radionuclide Conjugates (PRCs) Industry Trends
  2. 2.2 Peptide-Radionuclide Conjugates (PRCs) Industry Drivers
  3. 2.3 Peptide-Radionuclide Conjugates (PRCs) Industry Opportunities and Challenges
  4. 2.4 Peptide-Radionuclide Conjugates (PRCs) Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region
  3. 3.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region (2021-2026)
  5. 3.2.3 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region (2027-2032)
  6. 3.2.4 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region
  9. 3.4.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region (2021-2026)
  11. 3.4.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region (2027-2032)
  12. 3.4.4 Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Manufacturers
  2. 4.1.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Peptide-Radionuclide Conjugates (PRCs) Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Manufacturers
  6. 4.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Peptide-Radionuclide Conjugates (PRCs) Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Peptide-Radionuclide Conjugates (PRCs) Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Peptide-Radionuclide Conjugates (PRCs) Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Peptide-Radionuclide Conjugates (PRCs) Manufacturers, Product Type & Application
  13. 4.7 Global Peptide-Radionuclide Conjugates (PRCs) Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Peptide-Radionuclide Conjugates (PRCs) Market CR5 and HHI
  16. 4.8.2 2025 Peptide-Radionuclide Conjugates (PRCs) Tier 1, Tier 2, and Tier 3
5 Peptide-Radionuclide Conjugates (PRCs) Market by Type
  1. 5.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type
  2. 5.1.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type
  6. 5.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021-2032)
  9. 5.3 Global Peptide-Radionuclide Conjugates (PRCs) Price by Type
6 Peptide-Radionuclide Conjugates (PRCs) Market by Application
  1. 6.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application
  2. 6.1.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application
  6. 6.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2021-2032)
  9. 6.3 Global Peptide-Radionuclide Conjugates (PRCs) Price by Application
7 Company Profiles
  1. 7.1 Grand Pharmaceutical
  2. 7.1.1 Grand Pharmaceutical Company Information
  3. 7.1.2 Grand Pharmaceutical Business Overview
  4. 7.1.3 Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
  6. 7.1.5 Grand Pharmaceutical Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Novartis Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 Telix Pharmaceutical
  14. 7.3.1 Telix Pharmaceutical Company Information
  15. 7.3.2 Telix Pharmaceutical Business Overview
  16. 7.3.3 Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
  18. 7.3.5 Telix Pharmaceutical Recent Developments
  19. 7.4 RadioMedix
  20. 7.4.1 RadioMedix Company Information
  21. 7.4.2 RadioMedix Business Overview
  22. 7.4.3 RadioMedix Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 RadioMedix Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
  24. 7.4.5 RadioMedix Recent Developments
  25. 7.5 ITM Radiopharma
  26. 7.5.1 ITM Radiopharma Company Information
  27. 7.5.2 ITM Radiopharma Business Overview
  28. 7.5.3 ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
  30. 7.5.5 ITM Radiopharma Recent Developments
  31. 7.6 Curium Pharma
  32. 7.6.1 Curium Pharma Company Information
  33. 7.6.2 Curium Pharma Business Overview
  34. 7.6.3 Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
  36. 7.6.5 Curium Pharma Recent Developments
8 North America
  1. 8.1 North America Peptide-Radionuclide Conjugates (PRCs) Market Size by Type
  2. 8.1.1 North America Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021-2032)
  3. 8.1.2 North America Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2032)
  4. 8.1.3 North America Peptide-Radionuclide Conjugates (PRCs) Price by Type (2021-2032)
  5. 8.2 North America Peptide-Radionuclide Conjugates (PRCs) Market Size by Application
  6. 8.2.1 North America Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021-2032)
  7. 8.2.2 North America Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2032)
  8. 8.2.3 North America Peptide-Radionuclide Conjugates (PRCs) Price by Application (2021-2032)
  9. 8.3 North America Peptide-Radionuclide Conjugates (PRCs) Market Size by Country
  10. 8.3.1 North America Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Peptide-Radionuclide Conjugates (PRCs) Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Peptide-Radionuclide Conjugates (PRCs) Market Size by Type
  2. 9.1.1 Europe Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021-2032)
  3. 9.1.2 Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2032)
  4. 9.1.3 Europe Peptide-Radionuclide Conjugates (PRCs) Price by Type (2021-2032)
  5. 9.2 Europe Peptide-Radionuclide Conjugates (PRCs) Market Size by Application
  6. 9.2.1 Europe Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021-2032)
  7. 9.2.2 Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2032)
  8. 9.2.3 Europe Peptide-Radionuclide Conjugates (PRCs) Price by Application (2021-2032)
  9. 9.3 Europe Peptide-Radionuclide Conjugates (PRCs) Market Size by Country
  10. 9.3.1 Europe Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Peptide-Radionuclide Conjugates (PRCs) Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Peptide-Radionuclide Conjugates (PRCs) Market Size by Type
  2. 10.1.1 China Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021-2032)
  3. 10.1.2 China Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2032)
  4. 10.1.3 China Peptide-Radionuclide Conjugates (PRCs) Price by Type (2021-2032)
  5. 10.2 China Peptide-Radionuclide Conjugates (PRCs) Market Size by Application
  6. 10.2.1 China Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021-2032)
  7. 10.2.2 China Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2032)
  8. 10.2.3 China Peptide-Radionuclide Conjugates (PRCs) Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Peptide-Radionuclide Conjugates (PRCs) Market Size by Type
  2. 11.1.1 Asia Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021-2032)
  3. 11.1.2 Asia Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2032)
  4. 11.1.3 Asia Peptide-Radionuclide Conjugates (PRCs) Price by Type (2021-2032)
  5. 11.2 Asia Peptide-Radionuclide Conjugates (PRCs) Market Size by Application
  6. 11.2.1 Asia Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021-2032)
  7. 11.2.2 Asia Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2032)
  8. 11.2.3 Asia Peptide-Radionuclide Conjugates (PRCs) Price by Application (2021-2032)
  9. 11.3 Asia Peptide-Radionuclide Conjugates (PRCs) Market Size by Country
  10. 11.3.1 Asia Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Peptide-Radionuclide Conjugates (PRCs) Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Peptide-Radionuclide Conjugates (PRCs) Market Size by Type
  2. 12.1.1 SAMEA Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Peptide-Radionuclide Conjugates (PRCs) Price by Type (2021-2032)
  5. 12.2 SAMEA Peptide-Radionuclide Conjugates (PRCs) Market Size by Application
  6. 12.2.1 SAMEA Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Peptide-Radionuclide Conjugates (PRCs) Price by Application (2021-2032)
  9. 12.3 SAMEA Peptide-Radionuclide Conjugates (PRCs) Market Size by Country
  10. 12.3.1 SAMEA Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Peptide-Radionuclide Conjugates (PRCs) Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Peptide-Radionuclide Conjugates (PRCs) Value Chain Analysis
  2. 13.1.1 Peptide-Radionuclide Conjugates (PRCs) Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Peptide-Radionuclide Conjugates (PRCs) Production Mode & Process
  6. 13.2 Peptide-Radionuclide Conjugates (PRCs) Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Peptide-Radionuclide Conjugates (PRCs) Distributors
  9. 13.2.3 Peptide-Radionuclide Conjugates (PRCs) Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst